Moderna, Inc.

MRNA

Moderna, Inc.

MRNA

Insider Sentiment (TTM):

Last Purchase:2025-03-03Last Sale:2026-06-15Shares Purchased (TTM):0Shares Sold (TTM):323,339

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:303,166,702Shares Outstanding:395,000,000Institutional Ownership Pct.:76.75%

Earnings Market Reaction:

Filing Date:2026-05-01Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB RVMD NBIX

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	1,908	2,595	1,132	1,279	1,623	1,927	1,644	2,478	2,051	2,907	2,932	3,801
Available For Sale Securities Debt Securities Curr…	3,297	3,204	3,372	3,852	4,352	5,098	5,223	6,010	6,472	5,697	4,641	4,658
Accounts Receivable Net Current	71	184	1,046	36	78	358	1,564	163	137	892	1,866	232
Inventory Net	146	153	332	240	128	117	412	399	295	202	487	715
Prepaid Expense And Other Assets Current	348	408	716	764	585	599	823	611	645	627	873	1,193
Assets Current	5,770	6,544	6,598	6,171	6,766	8,099	9,666	9,661	9,600	10,325	10,799	10,599
Available For Sale Securities Debt Securities Nonc…	2,251	2,336	2,143	2,374	2,418	2,494	2,335	2,326	3,638	4,677	5,273	6,105
Property Plant And Equipment And Finance Lease Rig…	2,086	2,134	2,126	2,169	2,212	2,196	2,381	2,196	2,063	1,945	1,952	2,280
Operating Lease Right Of Use Asset	706	719	738	750	752	759	784	775	697	713	765	130
Deferred Income Tax Assets Net	-	-	-	-	-	-	81	81	81	81	0	1,480
Other Assets Noncurrent	675	605	530	546	556	594	556	641	650	766	661	1,290
Assets	11,488	12,338	12,135	12,010	12,704	14,142	15,803	15,680	16,729	18,426	19,450	21,884
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	161	317	267	175	226	405	373	279	183	520	494	310
Accrued Liabilities Current	1,912	1,386	1,178	987	1,001	1,427	1,376	1,333	1,396	1,798	2,224	1,490
Contract With Customer Liability Current	102	99	163	218	125	153	379	702	559	568	1,372	1,040
Taxes Payable Current	-	-	-	-	-	-	4	7	52	63	56	47
Other Liabilities Current	220	185	73	192	252	221	69	42	190	129	239	236
Liabilities Current	2,395	1,987	1,681	1,572	1,604	2,206	2,201	2,363	2,380	3,015	4,385	3,123
Contract With Customer Liability Noncurrent	154	153	157	65	58	58	95	95	58	83	166	692
Operating Lease Liability Noncurrent	645	653	660	666	667	671	679	668	637	643	697	104
Finance Lease Liability Noncurrent	13	20	26	32	35	39	625	576	575	575	575	843
Long Term Debt Noncurrent	590	590	-	-	-	0	-	-	-	-	-	-
Other Liabilities Noncurrent	283	285	281	276	274	267	276	266	262	256	172	173
Liabilities	4,080	3,688	2,805	2,611	2,638	3,241	3,876	3,968	3,912	4,572	5,995	4,935
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,503	1,382	1,254	1,127	982	866	751	631	487	371	277	193
Accumulated Other Comprehensive Income Loss Net Of…	25	45	27	23	10	-10	11	-71	-101	-123	-211	-263
Retained Earnings Accumulated Deficit	5,880	7,223	8,049	8,249	9,074	10,045	11,165	11,152	12,431	13,606	13,389	17,019
Stockholders Equity	7,408	8,650	9,330	9,399	10,066	10,901	11,927	11,712	12,817	13,854	13,455	16,949
Liabilities And Stockholders Equity	11,488	12,338	12,135	12,010	12,704	14,142	15,803	15,680	16,729	18,426	19,450	21,884
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	162	162	162	162	162	162	162	162	162	162	162	162
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	1,600	1,600	1,600	1,600	1,600	1,600	1,600	1,600	1,600	1,600	1,600	1,600
Common Stock Shares Issued	397	394	391	389	387	386	385	384	383	382	381	381
Shares Outstanding	397	394	391	389	387	386	385	384	383	382	381	381

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.33%	40.97%	-	-	-	-	-	-	-	-	-	-
2025	-2.85%	-4.18%	15.65%	-1.76%	-8.57%	-5.78%	6.78%	28.24%	100.21%	5.39%	2.19%	8.98%
2024	32.66%	6.22%	-3.54%	-12.46%	-30.24%	-42.55%	-14.36%	-20.19%	-17.64%	-2.56%	-26.26%	-31.75%
2023	-6.02%	-11.78%	-5.88%	1.80%	-9.06%	-26.88%	1.28%	22.39%	28.60%	7.66%	9.00%	21.62%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.41	3.29	3.93	3.93	4.22	3.67	4.39	4.09	4.03	3.42	2.46	3.39
Quick Ratio	2.20	3.01	3.30	3.29	3.77	3.35	3.83	3.66	3.64	3.15	2.15	2.78
Working Capital	3.38B	4.56B	4.92B	4.60B	5.16B	5.89B	7.47B	7.30B	7.22B	7.31B	6.41B	7.48B
Leverage & Debt
Debt to Equity	0.55	0.43	0.30	0.28	0.26	0.30	0.32	0.34	0.31	0.33	0.45	0.29
Debt Ratio	0.36	0.30	0.23	0.22	0.21	0.23	0.25	0.25	0.23	0.25	0.31	0.23
Efficiency & Turnover
Asset Turnover TTM	0.18	0.15	0.16	0.22	0.22	0.20	0.29	0.27	0.25	0.31	0.40	0.44
Days Sales Outstanding TTM	12.22	50.88	213.41	11.80	12.35	70.50	123.20	14.27	44.27	60.68	91.26	50.07
Receivables Turnover TTM	29.87	7.17	1.71	30.93	29.55	5.18	2.96	25.57	8.24	6.01	4.00	7.29
Per Share Metrics
Diluted EPS TTM	-8.09	-7.25	-7.99	-7.48	-8.70	-9.27	-5.57	-15.28	-15.62	-12.34	-9.10	3.17
Free Cash Flow Per Share TTM	-4.06	-5.31	-6.80	-8.99	-10.42	-10.56	-10.28	-10.36	-9.61	-10.01	-6.97	-1.98
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	22.11%	55.35%	48.25%	52.50%	54.11%	54.76%	67.45%	33.05%	22.43%	31.47%	37.70%	57.38%
Operating Profit Margin TTM	-153.35%	-158.13%	-155.15%	-106.34%	-117.37%	-121.91%	-53.00%	-91.78%	-99.73%	-61.90%	-29.22%	4.82%
Net Profit Margin TTM	-143.55%	-145.16%	-139.61%	-94.31%	-105.67%	-110.04%	-43.77%	-116.18%	-115.82%	-68.84%	-38.00%	11.33%
Growth Metrics
Net Revenue Growth (1Y)	-29.97%	-39.93%	-56.07%	-39.05%	-38.35%	-52.75%	-44.29%	-52.60%	-65.78%	-64.45%	-57.36%	-53.67%
Net Income Growth (1Y)	-4.86%	-20.75%	40.11%	-50.52%	-43.75%	-24.46%	-35.83%	-586.08%	-224.75%	-156.37%	-129.46%	-91.41%
EPS Growth (1Y)	-7.02%	-21.77%	38.31%	-51.03%	-44.33%	-24.85%	-36.50%	-582.28%	-226.06%	-158.14%	-130.16%	-91.07%
Valuation Metrics
P/E TTM	-6.28	-4.07	-3.23	-3.69	-3.26	-4.48	-11.57	-7.77	-6.82	-8.06	-11.35	38.35
P/B TTM	2.71	1.33	1.08	1.14	1.09	1.46	2.16	3.89	3.18	2.74	2.92	2.73
P/S TTM	9.02	5.90	4.51	3.48	3.44	4.93	5.06	9.03	7.90	5.55	4.31	4.34
Market Cap	20.07B	11.47B	10.07B	10.70B	10.94B	15.97B	25.73B	45.60B	40.71B	37.99B	39.35B	46.29B
Enterprise Value	18.75B	9.46B	8.97B	9.46B	9.35B	14.08B	24.71B	43.70B	39.21B	35.64B	36.98B	43.31B
Calculated Values
Free Cash Flow TTM	-1.60B	-2.07B	-2.65B	-3.49B	-4.02B	-4.06B	-3.96B	-3.98B	-3.67B	-3.83B	-2.66B	-754.00M
Net Debt	-1.32B	-2.01B	-1.11B	-1.25B	-1.59B	-1.89B	-1.02B	-1.90B	-1.50B	-2.35B	-2.38B	-2.98B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-15Sale

Owner: Hoge, Stephen

Title: President

Shares: 53,336

Price/Share: $51.37

Value: $2,739,870.32

Shares Owned: 1,483,848

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Klinger, Shannon Thyme

Title: Chief Legal Officer

Shares: 3,471

Price/Share: $50.00

Value: $173,550.00

Shares Owned: 67,468

Relationship: Officer

Ownership: Direct

2026-05-21Sale

Owner: Afeyan, Noubar

Title: -

Shares: 9,263

Price/Share: $46.84

Value: $433,878.92

Shares Owned: 3,924

Relationship: Director

Ownership: Indirect

2026-05-15Sale

Owner: Hoge, Stephen

Title: President

Shares: 53,336

Price/Share: $48.40

Value: $2,581,462.40

Shares Owned: 1,477,997

Relationship: Officer

Ownership: Direct

2026-05-01Sale

Owner: Hussain, Abbas

Title: -

Shares: 5,682

Price/Share: $46.63

Value: $264,951.66

Shares Owned: 12,066

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-15	Hoge, Stephen	Officer	President	Direct	Sale	53,336	51.37	$2,739,870.32	1,483,848	4
2026-06-04	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	3,471	50.00	$173,550.00	67,468	4
2026-05-21	Afeyan, Noubar	Director	-	Indirect	Sale	9,263	46.84	$433,878.92	3,924	4
2026-05-15	Hoge, Stephen	Officer	President	Direct	Sale	53,336	48.40	$2,581,462.40	1,477,997	4
2026-05-01	Hussain, Abbas	Director	-	Direct	Sale	5,682	46.63	$264,951.66	12,066	4
2026-03-02	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	13,885	52.29	$726,046.65	59,689	4
2026-02-23	Hoge, Stephen	Officer	President	Direct	Sale	160,009	48.84	$7,814,839.56	1,457,427	4
2025-12-11	Afeyan, Noubar	Director	-	Indirect	Sale	23,853	29.49	$703,424.97	3,924	4
2025-12-09	Hussain, Abbas	Director	-	Direct	Sale	504	27.60	$13,910.40	1,515	4
2025-06-11	Hussain, Abbas	Director	-	Direct	Sale	312	28.00	$8,736.00	580	4
2025-03-03	Bancel, Stephane	Director,Officer	Chief Executive Officer	Indirect	Purchase	160,314	31.28	$5,014,621.92	9,210,686	4
2025-03-03	Sagan, Paul	Director	-	Indirect	Purchase	31,620	31.76	$1,004,251.20	312,027	4
2024-12-09	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	529	44.68	$23,635.72	20,446	4
2024-12-03	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	112	43.30	$4,849.60	19,837	4
2024-12-03	Hoge, Stephen	Officer	President	Direct	Sale	314	43.30	$13,596.20	1,443,904	4
2024-11-29	Hoge, Stephen	Officer	President	Direct	Sale	291	42.79	$12,451.89	1,443,567	4
2024-11-29	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	1,418	42.79	$60,676.22	19,717	4
2024-11-29	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	1,420	42.79	$60,761.80	11,066	4
2024-11-11	Hoge, Stephen	Officer	President	Direct	Sale	277	46.10	$12,769.70	1,443,248	4
2024-10-07	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	715	60.12	$42,985.80	9,505	4
2024-09-09	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	551	73.57	$40,537.07	18,154	4
2024-09-03	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	114	76.99	$8,776.86	17,566	4
2024-09-03	Hoge, Stephen	Officer	President	Direct	Sale	318	76.99	$24,482.82	1,443,002	4
2024-08-29	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	162	78.03	$12,640.86	8,767	4
2024-08-29	Hoge, Stephen	Officer	President	Direct	Sale	300	78.03	$23,409.00	1,442,668	4
2024-08-29	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	162	78.03	$12,640.86	17,447	4
2024-08-28	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	1,319	79.39	$104,715.41	17,280	4
2024-08-28	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	1,321	79.39	$104,874.19	8,600	4
2024-08-12	Hoge, Stephen	Officer	President	Direct	Sale	254	84.10	$21,361.40	1,442,357	4
2024-07-31	Afeyan, Noubar	Director	-	Direct	Sale	15,000	120.32	$1,804,800.00	2,224,015	4
2024-07-24	Afeyan, Noubar	Director	-	Direct	Sale	15,000	117.72	$1,765,800.00	2,239,015	4
2024-07-17	Afeyan, Noubar	Director	-	Direct	Sale	15,000	122.74	$1,841,100.00	2,254,015	4
2024-07-15	Hoge, Stephen	Officer	President	Direct	Sale	15,000	121.12	$1,816,800.00	1,442,089	4
2024-07-10	Afeyan, Noubar	Director	-	Direct	Sale	15,000	118.05	$1,770,750.00	2,269,015	4
2024-07-08	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	689	118.24	$81,467.36	7,269	4
2024-06-26	Afeyan, Noubar	Director	-	Direct	Sale	15,000	127.95	$1,919,250.00	2,284,015	4
2024-06-18	Afeyan, Noubar	Director	-	Direct	Sale	15,000	134.30	$2,014,500.00	2,299,015	4
2024-06-17	Hoge, Stephen	Officer	President	Direct	Sale	15,000	138.16	$2,072,400.00	1,457,089	4
2024-06-12	Afeyan, Noubar	Director	-	Direct	Sale	15,000	146.92	$2,203,800.00	2,314,015	4
2024-06-11	Afeyan, Noubar	Director	-	Indirect	Sale	202,832	148.84	$30,189,514.88	1,528,557	4
2024-06-10	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	5,178	148.09	$766,810.02	15,947	4
2024-06-05	Afeyan, Noubar	Director	-	Direct	Sale	15,000	150.66	$2,259,900.00	1,946,931	4
2024-06-03	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	691	140.72	$97,237.52	6,506	4
2024-06-03	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	122	140.72	$17,167.84	10,878	4
2024-06-03	Hoge, Stephen	Officer	President	Direct	Sale	339	140.72	$47,704.08	1,472,089	4
2024-05-29	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	183	144.50	$26,443.50	5,871	4
2024-05-29	Hoge, Stephen	Officer	President	Direct	Sale	341	144.50	$49,274.50	1,471,777	4
2024-05-29	Afeyan, Noubar	Director	-	Direct	Sale	20,000	144.42	$2,888,400.00	1,961,931	4
2024-05-29	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	183	144.50	$26,443.50	10,768	4
2024-05-28	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	1,296	162.47	$210,561.12	10,623	4
2024-05-28	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	648	162.47	$105,280.56	5,726	4
2024-05-22	Afeyan, Noubar	Director	-	Direct	Sale	15,000	154.27	$2,314,050.00	1,981,931	4
2024-05-15	Afeyan, Noubar	Director	-	Direct	Sale	15,000	127.55	$1,913,250.00	1,996,931	4
2024-05-15	Hoge, Stephen	Officer	President	Direct	Sale	15,000	127.49	$1,912,350.00	1,471,508	4
2024-05-10	Hoge, Stephen	Officer	President	Direct	Sale	255	120.96	$30,844.80	1,486,508	4
2024-05-08	Afeyan, Noubar	Director	-	Direct	Sale	15,000	121.34	$1,820,100.00	2,011,931	4
2024-05-01	Afeyan, Noubar	Director	-	Direct	Sale	15,000	111.57	$1,673,550.00	2,026,931	4
2024-04-24	Afeyan, Noubar	Director	-	Direct	Sale	15,000	108.60	$1,629,000.00	2,041,931	4
2024-04-17	Afeyan, Noubar	Director	-	Direct	Sale	15,000	103.76	$1,556,400.00	2,056,931	4
2024-04-15	Hoge, Stephen	Officer	President	Direct	Sale	15,000	105.02	$1,575,300.00	1,486,241	4
2024-04-10	Afeyan, Noubar	Director	-	Direct	Sale	15,000	107.96	$1,619,400.00	2,071,931	4
2024-04-08	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	705	101.93	$71,860.65	5,048	4
2024-04-03	Afeyan, Noubar	Director	-	Direct	Sale	15,000	101.33	$1,519,950.00	2,086,931	4
2024-03-27	Afeyan, Noubar	Director	-	Direct	Sale	15,000	108.38	$1,625,700.00	2,101,931	4
2024-03-20	Afeyan, Noubar	Director	-	Direct	Sale	15,000	102.13	$1,531,950.00	2,116,931	4
2024-03-15	Hoge, Stephen	Officer	President	Direct	Sale	15,000	103.17	$1,547,550.00	1,501,241	4
2024-03-13	Afeyan, Noubar	Director	-	Direct	Sale	15,000	109.60	$1,644,000.00	2,131,931	4
2024-03-08	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	544	99.05	$53,883.20	9,267	4
2024-03-04	Hoge, Stephen	Officer	President	Direct	Sale	309	94.34	$29,151.06	1,516,241	4
2024-03-04	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	117	94.34	$11,037.78	8,673	4
2024-02-29	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	670	94.57	$63,361.90	8,557	4
2024-02-29	Hoge, Stephen	Officer	President	Direct	Sale	2,388	94.57	$225,833.16	1,515,898	4
2024-02-29	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	647	94.57	$61,186.79	4,300	4
2024-02-22	Hoge, Stephen	Officer	President	Direct	Sale	15,000	100.00	$1,500,000.00	1,513,433	4
2024-02-16	Hoge, Stephen	Officer	President	Direct	Sale	10,542	88.88	$936,972.96	1,528,433	4
2024-02-16	Bancel, Stephane	Director,Officer	Chief Executive Officer	Direct	Sale	26,351	88.88	$2,342,076.88	5,460,224	4
2024-02-12	Hoge, Stephen	Officer	President	Direct	Sale	304	86.23	$26,213.92	1,516,281	4
2024-01-16	Hoge, Stephen	Officer	President	Direct	Sale	15,000	103.90	$1,558,500.00	1,516,063	4
2024-01-08	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	772	109.75	$84,727.00	3,632	4
2023-12-27	Hoge, Stephen	Officer	President	Direct	Sale	45,000	100.01	$4,500,450.00	1,531,063	4
2023-12-08	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	563	79.09	$44,527.67	7,912	4
2023-12-06	Garay, Arpa	Officer	Chief Commercial Officer	Direct	Sale	564	78.34	$44,183.76	3,690	4
2023-12-04	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	111	79.31	$8,803.41	7,336	4
2023-12-04	Hoge, Stephen	Officer	President	Direct	Sale	309	79.31	$24,506.79	1,576,063	4
2023-11-29	Hoge, Stephen	Officer	President	Direct	Sale	1,136	79.81	$90,664.16	1,575,721	4
2023-11-10	Hoge, Stephen	Officer	President	Direct	Sale	263	68.76	$18,083.88	1,574,446	4
2023-11-01	Afeyan, Noubar	Director	-	Direct	Sale	10,000	75.74	$757,400.00	2,146,931	4
2023-10-25	Afeyan, Noubar	Director	-	Direct	Sale	10,000	77.50	$775,000.00	2,156,931	4
2023-10-11	Afeyan, Noubar	Director	-	Direct	Sale	15,000	104.26	$1,563,900.00	2,166,931	4
2023-10-06	Mock, James M	Officer	Chief Financial Officer	Direct	Sale	2,858	102.50	$292,945.00	2,952	4
2023-10-04	Afeyan, Noubar	Director	-	Direct	Sale	15,000	102.05	$1,530,750.00	2,181,931	4
2023-09-27	Afeyan, Noubar	Director	-	Direct	Sale	10,000	99.37	$993,700.00	2,196,931	4
2023-09-20	Afeyan, Noubar	Director	-	Direct	Sale	15,000	104.90	$1,573,500.00	2,206,931	4
2023-09-15	Hoge, Stephen	Officer	President	Direct	Sale	15,000	112.99	$1,694,850.00	1,574,187	4
2023-09-13	Afeyan, Noubar	Director	-	Direct	Sale	15,000	111.17	$1,667,550.00	2,221,931	4
2023-09-08	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	557	107.22	$59,721.54	7,215	4
2023-09-06	Garay, Arpa	Officer	Chief Commercial Officer	Direct	Sale	574	108.40	$62,221.60	3,113	4
2023-09-06	Afeyan, Noubar	Director	-	Direct	Sale	15,000	108.08	$1,621,200.00	1,982,209	4
2023-09-05	Klinger, Shannon Thyme	Officer	Chief Legal Officer	Direct	Sale	115	111.44	$12,815.60	6,634	4
2023-09-05	Hoge, Stephen	Officer	President	Direct	Sale	320	111.44	$35,660.80	1,589,187	4
2023-08-30	Afeyan, Noubar	Director	-	Direct	Sale	15,000	115.96	$1,739,400.00	1,997,209	4
2023-08-29	Hoge, Stephen	Officer	President	Direct	Sale	1,135	115.01	$130,536.35	1,588,855	4
2023-08-23	Afeyan, Noubar	Director	-	Direct	Sale	15,000	114.78	$1,721,700.00	2,012,209	4
2023-08-17	Hoge, Stephen	Officer	President	Direct	Sale	15,000	100.00	$1,500,000.00	1,587,579	4
2023-08-16	Afeyan, Noubar	Director	-	Direct	Sale	10,000	97.71	$977,100.00	2,027,209	4
2023-08-10	Hoge, Stephen	Officer	President	Direct	Sale	247	102.53	$25,324.91	1,602,579	4
2023-08-02	Afeyan, Noubar	Director	-	Direct	Sale	15,000	112.08	$1,681,200.00	2,037,209	4
2023-07-26	Afeyan, Noubar	Director	-	Direct	Sale	15,000	120.47	$1,807,050.00	2,052,209	4
2023-07-19	Afeyan, Noubar	Director	-	Direct	Sale	15,000	125.16	$1,877,400.00	2,067,209	4
2023-07-17	Hoge, Stephen	Officer	President	Direct	Sale	15,000	120.60	$1,809,000.00	1,602,303	4
2023-07-12	Afeyan, Noubar	Director	-	Direct	Sale	15,000	125.90	$1,888,500.00	2,082,209	4
2023-07-05	Afeyan, Noubar	Director	-	Direct	Sale	15,000	125.84	$1,887,600.00	2,097,209	4
2023-06-28	Bancel, Stephane	Director,Officer	Chief Executive Officer	Direct	Sale	27,155	121.71	$3,305,035.05	5,411,946	4
2023-06-28	Afeyan, Noubar	Director	-	Direct	Sale	15,000	121.33	$1,819,950.00	2,112,209	4
2023-06-22	Bancel, Stephane	Director,Officer	Chief Executive Officer	Direct	Sale	40,000	119.50	$4,780,000.00	5,411,946	4
2023-06-21	Afeyan, Noubar	Director	-	Direct	Sale	15,000	122.45	$1,836,750.00	2,127,209	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

76.75%

Inst. Shares: 303,166,702

Shares Outstanding: 395,000,000

2025-12-31

77.16%

Inst. Shares: 300,143,661

Shares Outstanding: 389,000,000

2025-09-30

69.11%

Inst. Shares: 269,531,163

Shares Outstanding: 390,000,000

2025-06-30

73.06%

Inst. Shares: 283,490,899

Shares Outstanding: 388,000,000

2025-03-31

70.64%

Inst. Shares: 272,660,294

Shares Outstanding: 386,000,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	303,166,702	395,000,000	76.75%
2025-12-31	300,143,661	389,000,000	77.16%
2025-09-30	269,531,163	390,000,000	69.11%
2025-06-30	283,490,899	388,000,000	73.06%
2025-03-31	272,660,294	386,000,000	70.64%
2024-12-31	269,076,883	384,000,000	70.07%
2024-09-30	250,193,661	385,000,000	64.99%
2024-06-30	255,071,907	384,000,000	66.42%
2024-03-31	252,428,651	382,000,000	66.08%
2023-12-31	249,690,726	382,000,000	65.36%
2023-09-30	235,157,619	381,000,000	61.72%
2023-06-30	237,876,944	381,000,000	62.43%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Moderna, Inc. (MRNA) — SEC Financial Statements & Analysis

Moderna, Inc. (MRNA) is a biological products, (no diagnostic substances) company, incorporated in DE. Moderna, Inc. trades on MRNA: Nasdaq as: MRNA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Moderna, Inc. reported a -29.97% year-over-year revenue growth, a Gross Profit Margin of 22.11% (TTM), a Debt-to-Equity ratio of 0.55x, a Price-to-Sales (P/S) ratio of 9.02x (TTM), a Price-to-Book (P/B) ratio of 2.71 (TTM), at a market cap of $20.07B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -29.97%
Gross Profit Margin TTM: 22.11%
Debt To Equity: 0.55x
P/S TTM: 9.02x
P/B TTM: 2.71
Market Cap: $20.07B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Moderna, Inc. in?

Moderna, Inc. (MRNA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is MRNA's market cap?

Moderna, Inc. (MRNA) has a market capitalization of $20.07B as of 2026-03-31.

What exchange does MRNA trade on?

Moderna, Inc. (MRNA) trades on the MRNA: Nasdaq.

Where is Moderna, Inc. incorporated?

Moderna, Inc. is incorporated in DE.

Moderna, Inc. (MRNA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.